



12/ from
Art West

PATENT
TECH CENTER 1600/2000

APR 10 2002

RECEIVED

Attorney Docket No.: VPHAR1460
(071243-130)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Desai, et. al.

Title: NOVEL FORMULATIONS OF
PHARMACOLOGICAL AGENTS,
METHODS FOR THE
PREPARATION THEREOF AND
METHODS FOR THE USE
THEREOF

Appl. No.: 09/446,783

Filing Date: May 16, 2000

Examiner: R. DeWitty

Art Unit: 1616

Commissioner for Patents
BOX IDS
Washington, D.C. 20231

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below.

Stephen E. Reiter
(Printed Name)

Stephan E. Reiter
(Signature)

April 3, 2002
(Date of Deposit)

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present

Applicant Desai, et. al.
Application No.: 09/446,783

PATENT
Attorney Docket No. VPHAR1460-2
(071243-1301)

2

application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.113, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

FEE

A fee in connection with submission of an information disclosure statement under 37 CFR §1.17(d) in the amount of \$180.00 in accordance with 37 CFR §1.17(p) is attached.

Applicant Desai, et. al.
Application No.: 09/446,783


PATENT
Attorney Docket No. VPHAR1460-2
(071243-1301)

3

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date: April 3, 2002

By 

FOLEY & LARDNER
P.O. Box 80278
San Diego, California 92138-0278
Telephone: (858) 847-6711
Facsimile: (858) 792-6773

Stephen E. Reiter
Attorney for Applicant
Registration No. 31,192